套细胞淋巴瘤:2017年诊断、风险分层与临床管理更新
套细胞淋巴瘤(MCL)是一种累及淋巴结、脾、血液和骨髓的非霍奇金淋巴瘤,标准治疗缓解持续时间短,中位总生存期(OS)为4-5年。诊断基于形态学、t(11:14)易位和cyclin D1免疫组化(98%病例阳性)。MIPI是最常用的预后模型,结合ECOG体能状态、年龄、白细胞计数和乳酸脱氢酶;风险适应治疗包括观察、强化化疗联合自体干细胞移植、R-CHOP或R-苯达莫司汀等。
要点
- 诊断依赖淋巴结、骨髓或组织形态学见中心细胞样小细胞或母细胞样细胞,t(11:14)为分子标志,cyclin D1免疫组化阳性率98%。
- MIPI风险分层:低危组中位OS未达到(5年OS 60%),中危组51个月,高危组29个月。
- 年轻中高危患者可考虑强化疗后自体干细胞移植,移植后利妥昔单抗维持改善无进展生存和总生存。
核心结论
- MCL标准治疗缓解持续时间短,中位OS为4-5年;诊断基于形态学、t(11:14)和cyclin D1免疫组化,MIPI用于风险分层,风险适应治疗包括观察、强化疗联合自体干细胞移植、R-CHOP或R-苯达莫司汀等。
研究设计与样本
- 综述,汇总MCL的诊断、风险分层和临床管理证据。
主要发现
- MCL中位OS为4-5年;cyclin D1免疫组化在98%病例中可检测到;SOX-11缺失或低Ki-67可能与更惰性形式相关。
- MIPI低危组中位OS未达到(5年OS 60%),中危组中位OS为51个月,高危组中位OS为29个月。
- 自体干细胞移植后利妥昔单抗维持治疗改善无进展生存和总生存;利妥昔单抗维持治疗可能延长无进展生存。
- 复发时,硼替佐米(NFkB抑制剂)、来那度胺(抗血管生成)和依鲁替尼(Bruton酪氨酸激酶[BTK]抑制剂)在MCL患者中显示出极好的临床活性。
关键数值与推荐
- 诊断依据淋巴结、骨髓或组织形态学见中心细胞样小细胞或母细胞样细胞;t(11:14)为分子标志导致cyclin D1过表达;cyclin D1免疫组化阳性率98%。
- MIPI包含ECOG体能状态、年龄、白细胞计数和乳酸脱氢酶;MIPI修改版若可获得还加入Ki-67增殖指数。
- 低危组MIPI中位OS未达到(5年OS 60%),中危组51个月,高危组29个月。
临床怎么用
- 对于选定的惰性、低MIPI MCL患者,初始观察可能是合适的治疗。
- 对于年轻的中危或高危MIPI MCL患者,应考虑强化疗方案后行自体干细胞移植;移植后利妥昔单抗维持治疗已改善无进展生存和总生存。
- 对于有症状的老年中危或高危MIPI MCL患者,应考虑R-CHOP、R-苯达莫司汀联合化疗或临床试验;利妥昔单抗维持治疗可能延长无进展生存。
- 复发时,可考虑靶向MCL细胞活化通路的药物如硼替佐米、来那度胺和依鲁替尼;年轻患者也可考虑自体或异基因干细胞移植;临床试验始终是MCL患者的考虑选项。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood and bone marrow with a short remission duration to standard therapies and a median overall survival (OS) of 4-5 years. DIAGNOSIS: Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation t (11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1. Cyclin D1 is detected by immunohistochemistry in 98% of cases. The absence of SOX-11 or a low Ki-67 may correlate with a more indolent form of MCL. The differential diagnosis of MCL includes small lymphocytic lymphoma, marginal zone lymphoma, and follicular lymphoma. RISK STRATIFICATION: The MCL International Prognostic Index (MIPI) is the prognostic model most often used and incorporates ECOG performance status, age, leukocyte count, and lactic dehydrogenase. A modification of the MIPI also adds the Ki-67 proliferative index if available. The median OS for the low-risk group was not reached (5-year OS of 60%). The median OS for the intermediate risk group was 51 months and 29 months for the high risk group. RISK-ADAPTED THERAPY: For selected indolent, low MIPI MCL patients, initial observation may be appropriate therapy. For younger patients with intermediate or high risk MIPI MCL, aggressive therapy with a cytotoxic Regimen followed by autologous stem cell transplantation should be considered. Rituximab maintenance after autologous stem cell transplantation has also improved the progression-free and overall survival. For older symptomatic MCL patients with intermediate or high risk MIPI, combination chemotherapy with R-CHOP, R-Bendamustine, or a clinical trial should be considered. In addition, rituximab maintenance therapy may prolong the progression-free survival. At the time of relapse, agents directed at activated pathways in MCL cells such as bortezomib (NFkB inhibitor), lenalidamide (anti-angiogenesis) and Ibruitinib (Bruton's Tyrosine Kinase [BTK] inhibitor) have demonstrated excellent clinical activity in MCL patients. Autologous or allogeneic stem cell transplantation can also be considered in young patients. Clinical trials with novel agents are always a consideration for MCL patients.
引用
- Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017. PMID: 28699667. doi:10.1002/ajh.24797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。